Equity Profile

CORT

Corcept Therapeutics Incorporated

Health CarePharmaceuticals$12.0B

Jul30Thu

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

Corcept Therapeutics Incorporated is a pharmaceutical company focused on developing and commercializing drugs to treat serious disorders related to the body's stress hormone, cortisol. With a market cap of $12 billion, it plays a significant role in the healthcare sector, particularly in addressing unmet medical needs in psychiatric and metabolic disorders.

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and is closely watched by investors.

0.36

Revenue

Revenue growth reflects the company's ability to expand its market presence and sales performance.

300M

Wall Street expectations, options signals, track record, and call prep available with Pro.

CORT Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

50%

Avg EPS Surprise

+4.94%

Avg Stock Reaction

-0.00%

Last Quarter Recap

In Q1-2026, Corcept reported an EPS of -$0.30, matching analyst expectations but showing no revenue figures. The stock experienced a slight decline of 0.15% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts expect Corcept to report an EPS of $0.36 and revenue of $300 million for Q2-2026, reflecting cautious optimism as the company continues to navigate its market.

Bull Case

If Corcept exceeds the EPS estimate, it could indicate stronger-than-expected demand for its products, potentially leading to a positive market reaction.

Bear Case

Conversely, if the company misses its EPS or revenue targets, it may raise concerns about its growth trajectory and market competitiveness.

Key Metrics to Watch

Earnings Per Share (EPS)

0.36

EPS is a key indicator of the company's profitability and is closely watched by investors.

Revenue

300M

Revenue growth reflects the company's ability to expand its market presence and sales performance.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will Corcept achieve an EPS of at least $0.36?

This number is crucial as it will indicate the company's profitability and ability to meet market expectations.

What revenue figures will Corcept report for Q2-2026?

Revenue performance is essential for assessing the company's growth potential and market demand for its products.

Edge

What the Street Is Missing

Why consensus could be wrong

The consensus may underestimate Corcept's ability to leverage its existing product line for revenue growth, especially in niche markets.

Supporting Evidence

The options market is pricing a 20.58% move, indicating significant uncertainty that may not align with the company's stable revenue streams.

Corcept's historical performance shows a mixed reaction to earnings, suggesting that the market may be overly cautious this quarter.

Key Risk

If Corcept's revenue exceeds $350 million, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating whether Corcept can sustain its growth trajectory amid increasing competition in the pharmaceutical sector.

Bull Confirmed If

An EPS of $0.38 or higher would confirm strong demand and operational efficiency.

Bear Confirmed If

An EPS below $0.34 would raise concerns about the company’s market position and growth prospects.

Pre-Earnings Positioning

Options Market

Implied Move

±20.58%

Historical Avg

±2.7%

Pricing rich

The options market is pricing in a significant move around the earnings report, suggesting heightened uncertainty among investors.

Options are pricing ±20.6% while CORT has averaged ±2.7% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.5%

30d HV

58.0%

Calls (72K)P/C Ratio: 1.21Puts (21K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Corcept beats expectations, history suggests the stock could see a modest increase, confirming positive market sentiment.

In-Line / Cautious

If the results are in line with expectations, the stock may experience limited movement as investors await further commentary from management.

Miss

A miss on EPS or revenue could lead to a decline in stock price, with historical patterns indicating a potential average drop of around 0.61%.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches or pipeline developments.
2Insights into market demand for existing products.
3Management's commentary on competitive pressures in the pharmaceutical industry.
4Guidance on future earnings and revenue expectations.
5Any strategic partnerships or collaborations that could enhance growth.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Jul27

KRCAMC

Kilroy Realty Corporation

PreviewView

Jul27

PIIAMC

Company Snapshot

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and is closely watched by investors.

0.36

Revenue

Revenue growth reflects the company's ability to expand its market presence and sales performance.

300M

Wall Street expectations, options signals, track record, and call prep available with Pro.

CORT Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

50%

Avg EPS Surprise

+4.94%

Avg Stock Reaction

-0.00%

Last Quarter Recap

In Q1-2026, Corcept reported an EPS of -$0.30, matching analyst expectations but showing no revenue figures. The stock experienced a slight decline of 0.15% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts expect Corcept to report an EPS of $0.36 and revenue of $300 million for Q2-2026, reflecting cautious optimism as the company continues to navigate its market.

Bull Case

If Corcept exceeds the EPS estimate, it could indicate stronger-than-expected demand for its products, potentially leading to a positive market reaction.

Bear Case

Conversely, if the company misses its EPS or revenue targets, it may raise concerns about its growth trajectory and market competitiveness.

Key Metrics to Watch

Earnings Per Share (EPS)

0.36

EPS is a key indicator of the company's profitability and is closely watched by investors.

Revenue

300M

Revenue growth reflects the company's ability to expand its market presence and sales performance.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will Corcept achieve an EPS of at least $0.36?

This number is crucial as it will indicate the company's profitability and ability to meet market expectations.

What revenue figures will Corcept report for Q2-2026?

Revenue performance is essential for assessing the company's growth potential and market demand for its products.

Edge

What the Street Is Missing

Why consensus could be wrong

The consensus may underestimate Corcept's ability to leverage its existing product line for revenue growth, especially in niche markets.

Supporting Evidence

The options market is pricing a 20.58% move, indicating significant uncertainty that may not align with the company's stable revenue streams.

Corcept's historical performance shows a mixed reaction to earnings, suggesting that the market may be overly cautious this quarter.

Key Risk

If Corcept's revenue exceeds $350 million, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating whether Corcept can sustain its growth trajectory amid increasing competition in the pharmaceutical sector.

Bull Confirmed If

An EPS of $0.38 or higher would confirm strong demand and operational efficiency.

Bear Confirmed If

An EPS below $0.34 would raise concerns about the company’s market position and growth prospects.

Pre-Earnings Positioning

Options Market

Implied Move

±20.58%

Historical Avg

±2.7%

Pricing rich

The options market is pricing in a significant move around the earnings report, suggesting heightened uncertainty among investors.

Options are pricing ±20.6% while CORT has averaged ±2.7% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.5%

30d HV

58.0%

Calls (72K)P/C Ratio: 1.21Puts (21K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Corcept beats expectations, history suggests the stock could see a modest increase, confirming positive market sentiment.

In-Line / Cautious

If the results are in line with expectations, the stock may experience limited movement as investors await further commentary from management.

Miss

A miss on EPS or revenue could lead to a decline in stock price, with historical patterns indicating a potential average drop of around 0.61%.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches or pipeline developments.
2Insights into market demand for existing products.
3Management's commentary on competitive pressures in the pharmaceutical industry.
4Guidance on future earnings and revenue expectations.
5Any strategic partnerships or collaborations that could enhance growth.